We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
Read MoreHide Full Article
Omnicell, Inc.’s (OMCL - Free Report) third-quarter 2019 adjusted earnings per share (EPS) of 76 cents outpaced the Zacks Consensus Estimate by 5.6%.
Also, adjusted EPS increased 20.6% from the year-ago figure and surpassed the company’s guided range of 67-72 cents as well.
Revenues in Detail
Revenues in the third quarter increased 11.9% year over year to $228.8 million. However, the top line missed the Zacks Consensus Estimate of $232.5 million.
Quarterly Details
On a segmental basis, Product revenues improved 12.6% year over year to $168.5 million in the reported quarter.
Moreover, Service and other revenues climbed 10.4% year over year to $60.3 million.
Operational Update
In the quarter under review, Omnicell's adjusted gross profit rose 12.4% to $115.5 million. Further, adjusted gross margin expanded 20 basis points (bps) to 50.5%.
However, adjusted operating expenses were $77.6 million in the third quarter, up 7% year over year. Meanwhile, adjusted operating profit totaled $37.9 million, reflecting a 25.1% jump from the prior-year quarter. Adjusted operating margin in the third quarter too grew 180 bps to 16.6%.
Financial Update
Omnicell exited the third quarter with cash and cash equivalents of $137.2 million compared with $87.5 million at the end of the second quarter.
Guidance
For the fourth quarter of 2019, Omnicell expects adjusted revenues between $240 million and $246 million. The Zacks Consensus Estimate for the metric stands at $244.3 million, within the guided range.
On an adjusted basis, product revenues are forecast between $181 million and $186 million while service revenues are projected within $59-$60 million.
Fourth-quarter adjusted EPS is envisioned in the band of 75-80 cents. The Zacks Consensus Estimate for the same is pegged at 81 cents, above the upper end of the predicted range.
For 2019, adjusted revenues are now anticipated within $889-$895 million, narrowed from the earlier band of $886-$900 million. The Zacks Consensus Estimate for the same is pegged at $896.7 million, ahead of the guided range.
Product revenues for the full year are tightened to $653-$658 million (earlier guidance was $653-$663 million) while service revenues are tapered between $236 million and $237 million (past estimate: $233-$237 million).
Adjusted EPS is forecast between $2.79 and $2.84 for 2019, raised from the earlier range of $2.65-$2.82. The Zacks Consensus Estimate for the metric stands at $2.79, in line with the lower end of the guided range.
Our Take
Omnicell delivered better-than-expected third-quarter 2019 adjusted earnings. Although revenues lagged the mark, the top line registered strong year-over-year growth. The company continued to see solid segmental contributions. Expansion of gross and operating margins in the reported quarter is encouraging as well. The company issued an upbeat guidance for the fourth quarter and lifted its 2019 EPS view.
Currently, the company is working on product innovation through R&D. Moving ahead, Omnicell is expected to gain traction from product launches, strategic partnerships and digital transformation.
However, a tough competitive landscape acts as a dampener.
Zacks Rank
Omnicell currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are ResMed, Inc. (RMD - Free Report) , Intutive Surgical, Inc. (ISRG - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) , all three carrying a Zacks Rank #2 (Buy).
ResMed reported first-quarter fiscal 2020 adjusted EPS of 93 cents, ahead of the Zacks Consensus Estimate by 6.9%. Revenues of $681.1 million too topped the consensus mark by 3.6%.
Intutive Surgical’ third-quarter 2019 adjusted EPS of $3.43 exceeded the Zacks Consensus Estimate by 21.2%. Moreover, revenues of $1.13 billion surpassed the consensus estimate of $1.06 billion. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion also beat the Zacks Consensus Estimate by 1.3%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Omnicell (OMCL) Beats on Q3 Earnings, Raises '19 EPS View
Omnicell, Inc.’s (OMCL - Free Report) third-quarter 2019 adjusted earnings per share (EPS) of 76 cents outpaced the Zacks Consensus Estimate by 5.6%.
Also, adjusted EPS increased 20.6% from the year-ago figure and surpassed the company’s guided range of 67-72 cents as well.
Revenues in Detail
Revenues in the third quarter increased 11.9% year over year to $228.8 million. However, the top line missed the Zacks Consensus Estimate of $232.5 million.
Quarterly Details
On a segmental basis, Product revenues improved 12.6% year over year to $168.5 million in the reported quarter.
Moreover, Service and other revenues climbed 10.4% year over year to $60.3 million.
Operational Update
In the quarter under review, Omnicell's adjusted gross profit rose 12.4% to $115.5 million. Further, adjusted gross margin expanded 20 basis points (bps) to 50.5%.
Omnicell, Inc. Price, Consensus and EPS Surprise
Omnicell, Inc. price-consensus-eps-surprise-chart | Omnicell, Inc. Quote
However, adjusted operating expenses were $77.6 million in the third quarter, up 7% year over year. Meanwhile, adjusted operating profit totaled $37.9 million, reflecting a 25.1% jump from the prior-year quarter. Adjusted operating margin in the third quarter too grew 180 bps to 16.6%.
Financial Update
Omnicell exited the third quarter with cash and cash equivalents of $137.2 million compared with $87.5 million at the end of the second quarter.
Guidance
For the fourth quarter of 2019, Omnicell expects adjusted revenues between $240 million and $246 million. The Zacks Consensus Estimate for the metric stands at $244.3 million, within the guided range.
On an adjusted basis, product revenues are forecast between $181 million and $186 million while service revenues are projected within $59-$60 million.
Fourth-quarter adjusted EPS is envisioned in the band of 75-80 cents. The Zacks Consensus Estimate for the same is pegged at 81 cents, above the upper end of the predicted range.
For 2019, adjusted revenues are now anticipated within $889-$895 million, narrowed from the earlier band of $886-$900 million. The Zacks Consensus Estimate for the same is pegged at $896.7 million, ahead of the guided range.
Product revenues for the full year are tightened to $653-$658 million (earlier guidance was $653-$663 million) while service revenues are tapered between $236 million and $237 million (past estimate: $233-$237 million).
Adjusted EPS is forecast between $2.79 and $2.84 for 2019, raised from the earlier range of $2.65-$2.82. The Zacks Consensus Estimate for the metric stands at $2.79, in line with the lower end of the guided range.
Our Take
Omnicell delivered better-than-expected third-quarter 2019 adjusted earnings. Although revenues lagged the mark, the top line registered strong year-over-year growth. The company continued to see solid segmental contributions. Expansion of gross and operating margins in the reported quarter is encouraging as well. The company issued an upbeat guidance for the fourth quarter and lifted its 2019 EPS view.
Currently, the company is working on product innovation through R&D. Moving ahead, Omnicell is expected to gain traction from product launches, strategic partnerships and digital transformation.
However, a tough competitive landscape acts as a dampener.
Zacks Rank
Omnicell currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are ResMed, Inc. (RMD - Free Report) , Intutive Surgical, Inc. (ISRG - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) , all three carrying a Zacks Rank #2 (Buy).
ResMed reported first-quarter fiscal 2020 adjusted EPS of 93 cents, ahead of the Zacks Consensus Estimate by 6.9%. Revenues of $681.1 million too topped the consensus mark by 3.6%.
Intutive Surgical’ third-quarter 2019 adjusted EPS of $3.43 exceeded the Zacks Consensus Estimate by 21.2%. Moreover, revenues of $1.13 billion surpassed the consensus estimate of $1.06 billion. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Revenues of $6.27 billion also beat the Zacks Consensus Estimate by 1.3%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>